Patient enrollment complete in Metadoxine Phase 3

Alcobra (ADHD +1.1%) completes patient enrollment for its Phase 3 clinical trial evaluating the safety and efficacy of Metadoxine Extended Release (MDX) in adult ADHD patients.

The trial is a 300-patient, randomized placebo-controlled study at 18 sites in the U.S. and two sites in Israel. The primary endpoint is a statistically significant improvement in ADHD symptoms versus placebo as measured by the Conners' Adult ADHD Rating Scale.

Comments (3)
  • mazlat10
    , contributor
    Comments (211) | Send Message
    how long until they come out with results?
    14 Jul 2014, 04:22 PM Reply Like
  • narfnas
    , contributor
    Comments (4) | Send Message
    do not know for sure - but trial path is 6 week monitoring after dosage - add time to digest data - minimum 8 weeks from now (likely more???). I don't think it is expected until late Q3.
    14 Jul 2014, 04:32 PM Reply Like
  • mazlat10
    , contributor
    Comments (211) | Send Message
    They said it should be released this quarter...
    15 Jul 2014, 07:56 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs